Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated with Ustekinumab
Phase of Trial: Phase III
Latest Information Update: 30 Dec 2018
At a glance
- Drugs Ustekinumab (Primary) ; Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms STARDUST
- Sponsors Janssen-Cilag
- 03 Oct 2018 Planned End Date changed from 25 Apr 2021 to 24 Jul 2021.
- 31 Aug 2018 Biomarkers information updated
- 18 Apr 2018 Planned End Date changed from 28 Feb 2021 to 25 Apr 2021.